Get the Stockscreener App
0.187
1.47%
0.0027
Pre-market:
.31
0.123
+65.78%
Plus Therapeutics Inc stock is traded at $0.187, with a volume of 120.58M.
It is up +1.47% in the last 24 hours and down -37.46% over the past month.
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).
See More
Previous Close:
$0.1843
Open:
$0.2127
24h Volume:
120.58M
Relative Volume:
9.69
Market Cap:
$11.45M
Revenue:
-
Net Income/Loss:
$-12.89M
P/E Ratio:
-0.0739
EPS:
-2.53
Net Cash Flow:
$-11.95M
1W Performance:
-39.40%
1M Performance:
-37.46%
6M Performance:
-82.69%
1Y Performance:
-88.31%
1-Day Range:
$0.172
$0.2194
1-Week Range:
$0.1634
$0.29
52-Week Range:
$0.1634
$2.3099
Plus Therapeutics Inc Stock (PSTV) Company Profile
Name
Plus Therapeutics Inc
Sector
Industry
Phone
737.255.7194
Address
4200 MARATHON BLVD., AUSTIN, TX
Compare PSTV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
0.187 | 11.45M | 0 | -12.89M | -11.95M | -2.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
450.27 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
522.27 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.00 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
568.06 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
266.80 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-25 | Initiated | D. Boral Capital | Buy |
| Jan-25-21 | Initiated | Ladenburg Thalmann | Buy |
| Oct-16-20 | Initiated | Maxim Group | Buy |
Plus Therapeutics Inc Stock (PSTV) Latest News
Dow Surges 150 Points; Korn Ferry Earnings Top Views - Benzinga
Plus Therapeutics (PSTV) Sees Stock Dip Amid New Share Sale Fili - GuruFocus
Plus Therapeutics drops 5%, files prospectus for 17M share secondary offering (PSTV:NASDAQ) - Seeking Alpha
Plus Therapeutics (PSTV) Announces Sale of 17 Million Shares | P - GuruFocus
Plus Therapeutics Modifies Security Holders’ Rights - TipRanks
Leptomeningeal Metastases Pipeline 2025: MOA, ROA, - openPR.com
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials - AlphaStreet
Plus Therapeutics Appeals Nasdaq Delisting Decision - TipRanks
Plus Therapeutics (NASDAQ:PSTV) Given New $20.50 Price Target at Ascendiant Capital Markets - Defense World
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds - mx.advfn.com
Ascendiant Capital raises Plus Therapeutics stock price target By Investing.com - Investing.com South Africa
Ascendiant Capital raises Plus Therapeutics stock price target - Investing.com
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price T - GuruFocus
PSTV: Ascendiant Capital Maintains Buy Rating and Raises Price Target | PSTV Stock News - GuruFocus
Plus Therapeutics (NASDAQ:PSTV) Shares Down 6.9% – Here’s What Happened - Defense World
Plus Therapeutics Reports Q1 2025 Financial Results - TipRanks
Plus Therapeutics (PSTV) Reports Significant Q1 Earnings Miss - GuruFocus
Plus Therapeutics (PSTV) Reports Q1 Loss, Misses Revenue Estimates - MSN
Plus: Q1 Earnings Snapshot - New Haven Register
Plus Therapeutics reports Q1 EPS ($1.19) vs. (75c) last year - TipRanks
Plus Therapeutics (PSTV) Reports Financial Gains from Grant Reve - GuruFocus
Earnings Flash (PSTV) Plus Therapeutics Reports Q1 Loss $-1.19 Per Share, vs. FactSet Est of $-0.25 - marketscreener.com
Plus Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights | PSTV Stock News - GuruFocus
Plus Therapeutics Reports First Quarter Financial Results and Recent Business Highlights - The Manila Times
PLUS THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Plus Therapeutics, Inc. Reports Q1 2025 Financial Results and Updates on REYOBIQ™ Trials and CNSide® Assay Platform Progress - Nasdaq
Plus Therapeutics Clinical Trial Success: Cancer Drug REYOBIQ Extends Patient Survival to 17 Months - Stock Titan
Should Plus Therapeutics Inc (NASDAQ: PSTV) Investors Be Concerned? - Stocksregister
DeFi Technologies Provides Monthly Corporate Update: Valour Reports C$1.18 Billion (US$819 Million) AUM, and Record Monthly Net Inflows of C$56 Million (US$38.8 Million) in December 2024 - The Globe and Mail
3 No-Brainer Cloud Computing Stocks to Buy Right Now - The Globe and Mail
Plus Therapeutics recives Nasdaq delinquency notice - MSN
Plus Therapeutics, Inc. Receives Notification of Deficiency from - GuruFocus
Plus Therapeutics (PSTV) Faces Nasdaq Compliance Challenge - GuruFocus
Plus Therapeutics Faces Nasdaq Compliance Notice - TipRanks
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q | PSTV Stock News - GuruFocus
Plus Therapeutics, Inc. Receives Notification of Deficiency - GlobeNewswire
Plus Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Quarterly Report on Form 10-Q - TradingView
SBAC Stock Rises 12% Year to Date: Will the Trend Continue? - The Globe and Mail
Plus Therapeutics soars on FDA Orphan Drug Designation for lung cancer treatment - MSN
Plus Therapeutics Receives Nasdaq Delisting Notice - TipRanks
Corpay Stock Jumps 25% in a Year: Here's What You Should Know - The Globe and Mail
Tesla Stock Powers Up for Fourth Straight Week of Gains - The Globe and Mail
Plus Therapeutics Delays Quarterly Report Filing - TipRanks
Plus Therapeutics (PSTV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - MSN
Plus Therapeutics reports progress in CNS cancer therapy By Investing.com - Investing.com Nigeria
Plus Therapeutics Inc Stock (PSTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Plus Therapeutics Inc Stock (PSTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 13 '24 |
Buy |
1.50 |
4,000 |
5,996 |
15,188 |
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):